Human T-cell lymphotropic virus type 1 in Adult
HTLV-1 virus is associated with ATL, a proliferation of CD4+ T-cells that can present in various forms. The lifetime risk of developing ATL after infection with HTLV-1 is approximately 2%-5%, and development occurs about 20-30 years after initial infection. The acute form is seen in most cases and has an aggressive course (approximate 6-month survival) presenting with skin lesions, hypercalcemia, bone lesions, and pulmonary infiltrates. Central nervous system (CNS) involvement can also occur. The lymphomatous form presents with lymphadenopathy, hepatosplenomegaly, and skin lesions. The chronic form has a slightly longer prognosis (approximately 2-year survival) and presents without hypercalcemia, CNS involvement, or gastrointestinal involvement. The smoldering form is the least common and has the best prognosis (survival of approximately 5 years); it is limited to skin and lung involvement only.
HTLV-1 is also associated with HAM. It is characterized by slow-onset weakness and spasticity in the lower extremities, hyperreflexia, back pain, urinary frequency / incontinence, paresthesias, and sensory changes. The upper limbs are spared. HAM occurs more commonly in women, and its severity is related to the proviral load found in the CNS.
HTLV-1-associated infective dermatitis (HTLV-1-associated ID) is a chronic, relapsing skin eruption that occurs in children more frequently than adults in the Caribbean and South America (most frequently in northeastern Brazil). HTLV-1 is thought to drive the immune dysregulation that is responsible for the eruption, and secondary infection with Staphylococcus aureus or β-hemolytic streptococci is common.
Related topic: human T-cell lymphotropic virus type 2
B97.33 – Human T-cell lymphotrophic virus, type I [HTLV-I] as the cause of diseases classified elsewhere
429659006 – Human T-cell lymphotropic virus 1 infection
Differential Diagnosis & Pitfalls